Bio-Path Shares Are Trading Higher After the Company Outlined Growing Evidence That Supports the Development of BP1001-A for the Treatment for Obestity and Related Metabolic Disease in Type 2 Diabetes Patients.
Bio-Path Shares Are Trading Higher After the Company Outlined Growing Evidence That Supports the Development of BP1001-A for the Treatment for Obestity and Related Metabolic Disease in Type 2 Diabetes Patients.
Bio-Path公司的股票在公司闡述了越來越多的證據支持開發BP1001-A用於治療2型糖尿病患者的肥胖及相關代謝疾病後，交易價格上漲。
Bio-Path Shares Are Trading Higher After the Company Outlined Growing Evidence That Supports the Development of BP1001-A for the Treatment for Obestity and Related Metabolic Disease in Type 2 Diabetes Patients.
Bio-Path 股價走高，此前該公司概述了越來越多的證據，這些證據支持開發 BP1001-A 用於治療 2 型糖尿病患者的肥胖和相關代謝性疾病。
資訊熱榜
更新時間